Skip to main content
OpenTrials
Completed

NCT Number: NCT03737045

Psoriatic Arthritis and Psoriasis Treatment Decision Aid

The purpose of this study is to create and test a patient decision aid that facilitates the shared decision-making process when patients with psoriasis and/or psoriatic arthritis are starting or switching to a new therapy.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Psoriatic Arthritis Arthritis Arthritis, Psoriatic Bone Diseases Joint Diseases Musculoskeletal Diseases Psoriasis Skin Diseases Skin Diseases, Papulosquamous Skin and Connective Tissue Diseases Spinal Diseases Spondylarthritis Spondylarthropathies Spondylitis

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Hospital at the University of Pennsylvania

Philadelphia, Pennsylvania, 19104, United States

About this study

Prior to the interventional study, we will develop a decision aid using design thinking. In this interventional study, we will implement and test a patient-centered decision aid for therapy selection among patients with psoriasis and/or psoriatic arthritis who are starting or switching to a new medication.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Age 18 years or older
  • Diagnosis of psoriasis (as confirmed by dermatologist) or psoriatic arthritis (as confirmed by rheumatologist)
  • Treated at Penn

In addition to the above, for the observation and implementation phases of the study:

  • Initiation of a new psoriasis or psoriatic arthritis treatment
  • Biosimilars that have been approved by the FDA and available on the US market will similarly be eligible for participation
  • Patients may be taking other traditional DMARDs.
  • A washout period is not required.

Exclusion criteria

  • Unable to give informed consent
  • Youth, under the age of 18 years
  • Patients without psoriasis or psoriatic arthritis
  • Not being treated at a Penn clinic

In addition to the above, for the observation and implementation phases of the study:

  • Not starting or switching to a new medication

Treatment and study plan

Decision Aid

Other

Participants will test decision aid prototypes that are designed to assist them in choosing a medication.

Primary outcomes

  1. Patient and provider self-reported perceptions of the decision aid as measured by satisfaction survey

    Time frame: Up to 24 months

    Satisfaction survey to rate the decision aid and shared decision-making process

Secondary outcomes

  1. Number of times decision aid was used in consultation for patients switching therapies or starting a new treatment.

    Time frame: Up to 24 months

    Rates of of the decision aid use

Sponsors and collaborators

Lead sponsor

University of Pennsylvania

Other

Collaborators

  • Pfizer

Registry information

Official study title

Developing a Patient-centered Patient Decision Aid for Psoriasis and/or Psoriatic Arthritis Using Design Thinking.

Acronym: DA

Important dates

Study start
2018
Primary completion
2025
Study completion
2025
First posted
Nov 9, 2018
Registry last updated
Feb 17, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.